Other substances

COV2-2130

An anti-RBD (SARS-CoV-2 Spike) human monoclonal antibody.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Experimental

Supporting references

Contradictory references

AI-suggested references

Clinical trials

General information

COV2-2130 is a human monoclonal antibody identified in serum of a COVID-19 convalescent patient. It bound SARS-CoV-2 Spike RBD and neutralized the live virus in vitro (Zost et al., 2020a). It was shown to act synergistically with COV2-2196 due to non-overlapping epitopes. The antibody prevented weight loss, decreased viral burden, and reduced lung inflammation in a mouse model after a viral challenge (Zost et al., 2021b). COV2-2130 is the parental antibody of Cilgavimab.

Supporting references

Link	Tested on	Impact factor	Notes	Publication date
Potently neutralizing and protective human antibodies against SARS-CoV-2 Spike protein ACE2 Biophysical assay Animal model In vitro Antibody	in vitro binding assay; in vitro biophysical assay; Vero E6 cells; BALB/c mice; rhesus macaques; SARS-CoV-2 pseudovirus; SARS-CoV-2 strain 2019 n-CoV/USA_WA1/2023	42.78	The antibody binds to Spike protein simultaneously with COV2-2196. The combination of antibodies is synergic in SARS-CoV-2 neutralization. COV2-2130 alone or combined with COV2-2196 displayed efficacy in a murine viral challenge model (reduction of weight loss, viral burden and lung inflammation).	Jul/15/2020
Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein Spike protein Novel compound Protein factor In vitro Antibody	Patient sera; Vero E6 cell; (VSV) SARS-CoV-2 Spike-pseudotyped virus; SARS-CoV-2 strain 2019 n-CoV/USA_WA1/2020	53.44	The antibody neutralized SARS-CoV-2 in vitro.	Jul/10/2020
Therapeutic efficacy of monoclonal antibodies and antivirals against SARS-CoV-2 Omicron BA.1 in Syrian hamsters 3CLpro Spike variant Novel compound Protein factor Small molecule Animal model Antibody	VeroE6/TMPRSS2 cells; Syrian hamsters; SARS-CoV-2 live virus (D614G, Omicron BA.1, and Omicron BA.1.1)	17.75	The antibody cocktail COV2-2196/COV2-2130 administered on day one post Syrian hamster viral challenge significantly decreased the viral titres of SARS-CoV-2 Omicron BA.1 in animals’ lungs. No significant decrease was observed in the case of nasal turbinates, or for the BA.1.1 strain, however.	Jun/15/2022
Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2 3CLpro Spike variant Protein factor Small molecule Animal model In vitro Antibody	VeroE6/TMPRSS2 cells; Syrian hamsters (K18-hACE2 lines); K18-hACE2 C57BL/6J mice; BALB/c mice; SARS-CoV-2 live virus (D614G, Delta, Omicron BA.1, Omicron BA.1.1, and Omicron BA.2 (various isolates))	49.96	The antibody cocktail COV2-2196/COV2-2130 administered on day one post Syrian hamster viral challenge significantly decreased the viral titres of SARS-CoV-2 Omicron BA.2 in animals’ lungs. No significant decrease was observed in the case of nasal turbinates, however.	May/16/2022

AI-suggested references

Link	Publication date
Characterization and antiviral susceptibility of SARS-CoV-2 Omicron/BA.2.	May/08/2020
A combination of two human neutralizing antibodies prevents SARS-CoV-2 infection in cynomolgus macaques	Jan/04/2022

Export (.csv)